2015 Investigation Report on China's Telmisartan Market 2010-2019

Aug 06, 2015, 09:10 ET from Research and Markets

DUBLIN, Aug. 06, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/lsr96f/investigation) has announced the addition of the "Investigation Report on China's Telmisartan Market, 2010-2019" report to their offering.

The number of hypertension patients in China is estimated to surpass 300 million with one in three adults suffering from it.

Out of all the dyazides, angiotension receptor blocker (ARB) is among a new generation which grows fast. Ever since the appearance of losartan which has been first applied in the clinic, 8 kinds of similar drugs have come out for sale and there are also 5 kinds of generic drugs in China. In recent years, telmisartan could be said as the fastest-growing kind of dyazide.

First developed by Boehringer-Ingelheim (Germany) and first marketed in the US in 1999 under the trade name of Micardis, telmisartan is an oral drug for the treatment of essential hypertension which should be taken once a day. It was marketed by Boehringer-Ingelheim under the trade name of Micardis and by Glaxo Wellcome plc under the trade name of Pritor in Germany in the same year. Telmisartan entered the Philippines in Dec. 1999 and Australia, Belgium, Britain in 2000. In 2013, its sales value surpassed USD 3 billion in the world. The patent of telmisartan expired in 2014.

The active pharmaceutical ingredients (APIs) and preparations of telmisartan were introduced by Boehringer-Ingelheim into China for sales at the end of 2000. After entering China, telmisartan grows fast with annual sales value rising from less than CNY 13 million in 2005 to CNY 200 million in 2014 and CAGR during this period reaching up to 35.8% despite a slight fall in 2014. Currently, telmisartan in the Chinese market mainly come from the following companies: Boehringer-Ingelheim (Germany), China Resources Double Crane Pharmaceutical Co., Ltd, Yichang Changjiang Pharmaceutical Co., Ltd, Wanbang Biopharmaceuticals and Hainan Selection Pharmaceutical Co., Ltd, among which Boehringer-Ingelheim (Germany) has the largest market share of over 80%, sales value in 2014 reaching up to CNY 167 million.

Key Topics Covered:

1 Related Concepts of Telmisartan

2 Market Profile of Telmisartan in China

3 Survey on Sales Status of Telmisartan in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Telmisartan in China, 2010-2014

5 Survey on Dosage Forms of Telmisartan in China, 2010-2014

6 Reference Price of Telmisartan in Chinese Hospitals in 2014

7 Major Manufacturers of Telmisartan in Chinese Market, 2010-2014

8 Market Outlook of Telmisartan in China, 2015-2019

Companies Mentioned

- Boehringer-Ingelheim
- China Resources Double Crane Pharmaceutical Co., Ltd
- Yichang Changjiang Pharmaceutical Co., Ltd
- Wanbang Biopharmaceuticals
- Hainan Selection Pharmaceutical Co., Ltd

For more information visit http://www.researchandmarkets.com/research/lsr96f/investigation

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com